MX2009011276A - Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad. - Google Patents

Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad.

Info

Publication number
MX2009011276A
MX2009011276A MX2009011276A MX2009011276A MX2009011276A MX 2009011276 A MX2009011276 A MX 2009011276A MX 2009011276 A MX2009011276 A MX 2009011276A MX 2009011276 A MX2009011276 A MX 2009011276A MX 2009011276 A MX2009011276 A MX 2009011276A
Authority
MX
Mexico
Prior art keywords
dpp
same
obesity
diabetes
pharmaceutical composition
Prior art date
Application number
MX2009011276A
Other languages
English (en)
Spanish (es)
Inventor
Moohi Yoo
Soon Hoe Kim
Heung Jae Kim
Woo Young Kwak
Chang Yell Shin
Hadong Kim
Jong Pil Min
Kyung Jin Park
Jae Young Lee
Song-Hyen Choi
Tae Hyun Yoon
Hae-Sun Kim
Ji Myun Jang
Mi-Kyung Kim
Moon-Ho Son
Original Assignee
Dong A Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong A Pharm Co Ltd filed Critical Dong A Pharm Co Ltd
Publication of MX2009011276A publication Critical patent/MX2009011276A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2009011276A 2007-04-19 2008-04-18 Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad. MX2009011276A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20070038462 2007-04-19
PCT/KR2008/002203 WO2008130151A1 (en) 2007-04-19 2008-04-18 Dpp-iv inhibitor including beta-amino group, preparation method thereof and pharmaceutical composition containing the same for preventing and treating a diabetes or an obesity

Publications (1)

Publication Number Publication Date
MX2009011276A true MX2009011276A (es) 2010-01-15

Family

ID=39875638

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2009011276A MX2009011276A (es) 2007-04-19 2008-04-18 Inhibidor de dpp-iv que incluye el grupo beta-amino, metodo para la preparacion del mismo y composicion farmaceutica que contiene el mismo para prevenir y tratar una diabetes o una obesidad.

Country Status (15)

Country Link
US (1) US8030315B2 (enExample)
EP (1) EP2142519B1 (enExample)
JP (1) JP5148686B2 (enExample)
KR (1) KR101007497B1 (enExample)
CN (2) CN102516184B (enExample)
AU (1) AU2008241692B2 (enExample)
BR (1) BRPI0810246B1 (enExample)
CA (1) CA2683696C (enExample)
ES (1) ES2526338T3 (enExample)
IL (1) IL201524A (enExample)
MX (1) MX2009011276A (enExample)
NZ (1) NZ580701A (enExample)
PT (1) PT2142519E (enExample)
RU (1) RU2419615C1 (enExample)
WO (1) WO2008130151A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101054911B1 (ko) * 2008-10-17 2011-08-05 동아제약주식회사 디펩티딜펩티다아제-ⅳ의 활성을 저해하는 화합물 및 다른 항당뇨 또는 항비만 약물을 유효성분으로 함유하는 당뇨 또는 비만의 예방 및 치료용 약학적 조성물
JP5475864B2 (ja) * 2009-03-30 2014-04-16 ドン ア ファーマシューティカル カンパニー リミテッド ジペプチジルペプチダーゼ−ｉｖ阻害剤及び中間体の改良された製造方法
SG174974A1 (en) 2009-03-30 2011-11-28 Dong A Pharm Co Ltd Improved method for preparing dipeptidyl peptidase-iv inhibitor and intermediate
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
KR20110107287A (ko) * 2010-03-24 2011-09-30 동아제약주식회사 비알콜성 지방간 질환의 예방 및 치료용 약학적 조성물
KR101180174B1 (ko) 2010-04-23 2012-09-05 동아제약주식회사 신규한 벤즈아미드 유도체
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
KR101290029B1 (ko) 2011-01-20 2013-07-30 에스티팜 주식회사 시타글립틴의 중간체 제조방법
CN102321014A (zh) * 2011-05-27 2012-01-18 沈阳亿灵医药科技有限公司 新型双苯基吡啶类衍生物
US20140336196A1 (en) * 2011-05-27 2014-11-13 Merck Sharp & Dohme Corp. Phosphoric acid salts of sitagliptin
WO2012170702A1 (en) 2011-06-08 2012-12-13 Arena Pharmaceuticals, Inc. Modulators of the gpr119 receptor and the treatment of disorders related thereto
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN105142621A (zh) 2012-10-24 2015-12-09 国家健康科学研究所 用于预防或治疗糖尿病和促进β-细胞存活的TPL2激酶抑制剂
CN105555275B (zh) * 2013-06-26 2021-04-20 东亚St株式会社 含有dpp-iv抑制剂的用于预防和治疗肾脏疾病的组合物
EP3273981B1 (en) 2015-03-24 2020-04-29 INSERM - Institut National de la Santé et de la Recherche Médicale Method and pharmaceutical composition for use in the treatment of diabetes
KR101709127B1 (ko) 2015-06-16 2017-02-22 경동제약 주식회사 Dpp-iv 억제제의 제조를 위한 신규 중간체, 이의 제조방법 및 이를 이용한 dpp-iv 억제제의 제조방법
CN107382757A (zh) * 2017-08-11 2017-11-24 苏州信恩医药科技有限公司 不对称烯丙基取代反应在依格列汀中间体合成中的应用
CN107417554A (zh) * 2017-08-15 2017-12-01 苏州信恩医药科技有限公司 一种依格列汀中间体的合成方法
KR20220165346A (ko) 2021-06-08 2022-12-15 동아에스티 주식회사 에보글립틴의 안정성이 개선된 제제

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1187342C (zh) * 2000-05-25 2005-02-02 弗·哈夫曼-拉罗切有限公司 取代的1－氨基烷基内酰胺化合物及其作为毒蕈碱受体拮抗剂的用途
DE60114413T2 (de) * 2000-05-25 2006-07-27 F. Hoffmann-La Roche Ag Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
JP2002088070A (ja) * 2000-09-18 2002-03-27 Mitsubishi Rayon Co Ltd 新規ピペラジノン誘導体およびその製造方法
WO2004032836A2 (en) * 2002-10-07 2004-04-22 Merck & Co., Inc. Antidiabetic beta-amino heterocylcic dipeptidyl peptidase inhibitors
HRP20050343A2 (en) 2002-10-18 2007-03-31 Merck & Co. Inc. Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
CN1882551A (zh) 2003-07-31 2006-12-20 麦克公司 用作用于治疗或预防糖尿病的二肽基肽酶－iv酶抑制剂的六氢二氮杂吖庚因酮
EP1541143A1 (en) * 2003-12-09 2005-06-15 Graffinity Pharmaceuticals Aktiengesellschaft Dpp-iv inhibitors
WO2005056541A1 (ja) * 2003-12-11 2005-06-23 Mitsubishi Pharma Corporation α-アミノ酸誘導体及びその医薬用途
EP1593671A1 (en) * 2004-03-05 2005-11-09 Graffinity Pharmaceuticals AG DPP-IV inhibitors
EP1604989A1 (en) * 2004-06-08 2005-12-14 Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft DPP-IV inhibitors
GB0413389D0 (en) 2004-06-16 2004-07-21 Astrazeneca Ab Chemical compounds
WO2006104997A2 (en) 2005-03-29 2006-10-05 Merck & Co., Inc. Tartaric acid salts of a dipeptidyl peptidase-iv inhibitor
JP2008031064A (ja) * 2006-07-27 2008-02-14 Astellas Pharma Inc ジアシルピペラジン誘導体

Also Published As

Publication number Publication date
JP5148686B2 (ja) 2013-02-20
BRPI0810246A2 (pt) 2015-08-18
IL201524A (en) 2014-09-30
BRPI0810246B1 (pt) 2021-11-30
WO2008130151A1 (en) 2008-10-30
AU2008241692A1 (en) 2008-10-30
CA2683696C (en) 2012-05-22
IL201524A0 (en) 2010-05-31
EP2142519B1 (en) 2014-09-24
US8030315B2 (en) 2011-10-04
EP2142519A4 (en) 2011-07-13
RU2419615C1 (ru) 2011-05-27
CN102516184B (zh) 2015-03-25
AU2008241692B2 (en) 2011-02-10
HK1138272A1 (en) 2010-08-20
CN102516184A (zh) 2012-06-27
CN101663282A (zh) 2010-03-03
NZ580701A (en) 2011-07-29
KR101007497B1 (ko) 2011-01-12
HK1172613A1 (en) 2013-04-26
PT2142519E (pt) 2014-12-11
JP2011500508A (ja) 2011-01-06
CA2683696A1 (en) 2008-10-30
KR20080094604A (ko) 2008-10-23
US20100120790A1 (en) 2010-05-13
EP2142519A1 (en) 2010-01-13
ES2526338T3 (es) 2015-01-09
CN101663282B (zh) 2012-02-15

Similar Documents

Publication Publication Date Title
WO2010021680A3 (en) Inhibitors of beta-secretase
WO2005075425A3 (en) Substituted bisarylurea derivatives as kinase inhibitors
WO2008001195A3 (en) Novel processes for the preparation of dpp iv inhibitors
TW200833663A (en) Therapeutic agents
TW200615266A (en) Organic compounds
EA017091B9 (ru) Фумаратная соль (альфа s, бета r)-6-бром-альфа-[2-(диметиламино)этил]-2-метокси-альфа-1-нафталенил-бета-фенил-3-хинолинэтанола
TN2010000019A1 (en) Solid preparation comprising alogliptin and metformin hydrochloride
MX2011011028A (es) Agonista del receptor beta de hormona tiroidea novedoso.
PH12013501594A1 (en) Substituted indazole derivatives active as kinase inhibitors
WO2004033455A3 (en) Hemisuccinate salts of heterocyclic dpp-iv inhibitors
WO2009155121A3 (en) Inhibitors of pi3 kinase
IN2014KN00948A (enExample)
SG179034A1 (en) 2 -aminodihydro [1, 3] thiazines as bace 2 inhibitors for the treatment of diabetes
TN2012000152A1 (en) Spiropiperidine compounds and pharmaceutical use thereof for treating diabetes
EA201070635A1 (ru) Соединения, ингибирующие дипептидилпептидазу-iv,способы их получения и фармацевтические композиции, содержащие их в качестве активного агента
WO2010016683A3 (ko) 탈모의 예방, 치료, 또는 육모용 조성물
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
MX2012003324A (es) Compuesto de glicina.
PH12019500394A1 (en) Bicyclic nitrogenated heterocyclic compound
EP4477222A3 (en) Crystalline 4-(5-chloro-2-isopropylaminopyridin-4-yl)-1h-pyrrole-2-carboxylic acid [1-(3-chlorophenyl)-2-hydroxyethyl]amide hydrochloride salt
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
MX344014B (es) Compuesto heterocíclico bicíclico.
EA200870223A1 (ru) Производные бензоизоиндола для лечения боли
WO2010038948A3 (en) Arylpiperazine-containing pyrrole 3-carboxamide derivatives for treating depressive disorders

Legal Events

Date Code Title Description
FG Grant or registration